Production of biologically active complement factor H in therapeutically useful quantities
about
Atypical hemolytic uremic syndromeComplement regulation: physiology and disease relevanceMembranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusionSolution Structure of CCP Modules 10–12 Illuminates Functional Architecture of the Complement Regulator, Factor HComplement Evasion Mediated by Enhancement of Captured Factor H: Implications for Protection of Self-Surfaces from ComplementPlasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes.Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndromeNovel use of intravenous immunoglobulin G in complement factor H missense mutation: a case report.Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.Lack of evidence from studies of soluble protein fragments that Knops blood group polymorphisms in complement receptor-type 1 are driven by malaria.Affinity purification of human factor H on polypeptides derived from streptococcal m protein: enrichment of the Y402 variantDense deposit disease.Characterization of Inhibitors and Monoclonal Antibodies That Modulate the Interaction between Plasmodium falciparum Adhesin PfRh4 with Its Erythrocyte Receptor Complement Receptor 1.Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.Factor h: a complement regulator in health and disease, and a mediator of cellular interactions.Biologic agents in the treatment of glomerulonephritides.Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies.Protection of host cells by complement regulators.Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation.Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's membrane: implications for age-related macular degeneration.Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome.An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.Two distinct conformations of factor H regulate discrete complement-binding functions in the fluid phase and at cell surfaces
P2860
Q21202864-E012DD16-7750-486F-8800-4865D9062999Q26795441-97AE3112-8EC8-40CD-A177-4F1F9CE0121DQ27008508-FD0A0D52-C92C-4482-85D5-E572AF67B09FQ27673696-AB3DC4DD-1C1A-4F21-8065-9B93584CB8D0Q28268485-8E17F416-E4BC-47C6-8B2C-C20BE2307E24Q30425504-058D1B19-3B5F-4345-878F-C66BE3E08188Q33396792-E7B70435-2172-4D29-82C7-35AE90D46C4EQ33410111-7EC67ED9-13D4-4219-96E6-147D6587AC50Q33437488-73286E73-312A-48AE-B701-D06551C2B43BQ34233738-9F60F750-FB73-4CE0-9423-F5149F217AA2Q35053992-8A621A69-B56F-4E12-820C-4E8D2991332EQ35124165-E4D0CF00-A769-4A64-A9ED-7C95EDB920EBQ36283289-C9F56C6F-1CF3-421D-917E-2D255418CABEQ36447625-6E8EEF65-4644-4620-9374-7CA7B248A4ECQ36463266-23CE58E9-4C6E-474A-AE63-9993607696EFQ36563619-A27F9045-5C3A-4652-80AD-10C7526762FAQ37300691-929CCA26-6F5B-489F-88C3-E92277F703EBQ38223669-B1AB7E67-78A3-4B43-995C-F33B65D0D2B2Q38514894-D672A668-F609-4240-95EC-8A9866934083Q38880897-68919B76-38ED-4F32-B4F3-7851AF6E98EFQ38991019-289DA755-09ED-45F7-ADA1-5B583A87B5A2Q41377869-98D76C36-8929-4DA6-8860-2EE4F3987C1AQ41705490-1994BF79-E756-4D1C-9537-1C8C03A4764CQ41875130-042F2A0E-005A-4EE0-B6AD-97640966071FQ42625961-10ED579E-53EC-4214-B4CF-6E80EB081644Q51730313-D0D86C49-E16D-42E1-A833-ECCAC7E1AFB5Q58738012-26328333-0FDA-480C-9C1F-46DED2D1B785
P2860
Production of biologically active complement factor H in therapeutically useful quantities
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Production of biologically act ...... rapeutically useful quantities
@ast
Production of biologically act ...... rapeutically useful quantities
@en
Production of biologically act ...... rapeutically useful quantities
@nl
type
label
Production of biologically act ...... rapeutically useful quantities
@ast
Production of biologically act ...... rapeutically useful quantities
@en
Production of biologically act ...... rapeutically useful quantities
@nl
prefLabel
Production of biologically act ...... rapeutically useful quantities
@ast
Production of biologically act ...... rapeutically useful quantities
@en
Production of biologically act ...... rapeutically useful quantities
@nl
P2093
P2860
P1476
Production of biologically act ...... rapeutically useful quantities
@en
P2093
Anna Richards
Christoph Q Schmidt
Fern C Slingsby
Paul N Barlow
P2860
P304
P356
10.1016/J.PEP.2010.12.002
P407
P577
2011-04-01T00:00:00Z